marinedrugs-logo

Journal Browser

Journal Browser

Marine Natural Products and Gut Microbiota: From Interactions to Metabolic Health

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine-Derived Ingredients for Drugs, Cosmeceuticals and Nutraceuticals".

Deadline for manuscript submissions: 30 November 2026 | Viewed by 920

Editors


E-Mail Website
Guest Editor
State Key Laboratory for Quality and Safety of Agro-Products, Institute of Food Sciences, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China
Interests: functional foods; precise nutrition; gut microbiota

E-Mail Website
Guest Editor
School of Food and Pharmacy, Zhejiang Ocean University, Zhoushan, China
Interests: natural product; marine microbiota; metabolic health
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Gut dysbiosis, impaired intestinal barrier integrity, and chronic inflammation are now recognized as central drivers of metabolic disorders, including obesity, diabetes, inflammatory bowel disease, and nonalcoholic fatty liver disease. Despite advances in the field, effective nutritional interventions remain limited.

The ocean represents an underexplored reservoir of structurally unique bioactive compounds. Marine natural products, particularly polysaccharides such as fucoidan, alginate, and chitosan, as well as polyphenols and peptides, have shown promising abilities to modulate gut microbiota composition, enhance intestinal barrier function, regulate microbial metabolites such as SCFAs, indole derivatives, and secondary bile acids, and alleviate gut inflammation.

This Special Issue aims to highlight cutting-edge research on marine natural products for gut health, with a strong emphasis on molecular targets and mechanistic insights. We welcome innovative approaches, including in vitro fermentation models, in vivo studies, organoid and 3D co-culture systems, as well as multi-omics analyses. Contributions exploring synergistic combinations with probiotics, prebiotics, or other bioactive agents are particularly encouraged. Papers addressing the immunomodulatory and barrier protective effects of marine compounds, whether used alone or alongside existing therapies, are also of great interest.

We invite researchers from academia and industry to submit original research articles, comprehensive reviews, and concept papers that advance our understanding of marine-derived interventions for gut and metabolic health.

Dr. Xiaoqiong Li
Prof. Dr. Yadong Zhao
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine polysaccharides
  • gut microbiota
  • metabolic health
  • intestinal barrier
  • prebiotic

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 9881 KB  
Article
Fermentation of Structurally Defined Alginate Oligosaccharides by the Human Gut Microbiota Enriched in Bifidobacterium, Bacteroides, Faecalibacterium, or Blautia
by Siyu Liu, Yuchen Wu, Youjing Lv, Meng Shao, Depeng Lv, Quancai Li and Qingsen Shang
Mar. Drugs 2026, 24(7), 239; https://doi.org/10.3390/md24070239 - 7 Jul 2026
Viewed by 686
Abstract
Alginate oligosaccharides (AOS) are attractive candidates for prebiotic development, yet how oligosaccharide structure and baseline microbial community composition interact to shape fermentation remains an open question. In this study, we stratified fecal microbiota from healthy donors into operational genus-predominance groups (Bifidobacterium, [...] Read more.
Alginate oligosaccharides (AOS) are attractive candidates for prebiotic development, yet how oligosaccharide structure and baseline microbial community composition interact to shape fermentation remains an open question. In this study, we stratified fecal microbiota from healthy donors into operational genus-predominance groups (Bifidobacterium, Bacteroides, Faecalibacterium, or Blautia) and selected representative samples for in vitro fermentation of six structurally distinct AOS preparations (SAOS-1, SAOS-2, OAOS, UAOS, SMOS, and SGOS). Substrate consumption, short-chain fatty acid (SCFA) production, and shifts in microbial community structure were profiled. The six preparations differed in structural type, number-average molecular weight, and average degree of polymerization. Among them, SAOS-1 exhibited the most consistent utilization across all four groups and yielded the highest total SCFA production. SAOS-1 fermentation also attenuated inter-group community divergence and enriched several beneficial or functionally relevant taxa, including Bacteroides and Faecalibacterium. Interestingly, the magnitude and direction of microbial responses remained enterotype-dependent, with the Bacteroides-predominant group assembling the most complex fermentative consortium. These findings demonstrate that AOS structure and baseline microbial ecology jointly dictate fermentation outcomes, positioning SAOS-1 as a strong candidate for precision prebiotic development. This structure–community interaction paradigm provides a rational basis for the targeted deployment of marine oligosaccharides in personalized gut health strategies. Full article
Show Figures

Graphical abstract

Back to TopTop